

Cadeirydd/Chair: **Emma Woollett** Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 3rd June 2020 Ein Cyf / Our Ref: 20-E-015 © 01639 648363 FOIA.Requests@wales.nhs.uk

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

Dear

I refer to your Freedom of Information Act Request acknowledged by ourselves on 15th May 2020. Your request sought information relating to medication numbers.

Please note the information provided is for the period 01.02.2020 - 30.04.2020.

Could you please provide me with the following numbers of patients treated in the last 3 months with the following drugs, regardless of disease;

Abatacept [Orencia] - 63

Adalimumab [Amgevita] - 151

Adalimumab [Hulio] - 0

Adalimumab [Humira] - 114

Adalimumab [Hyrimoz] - 0

Adalimumab [Imraldi] - 375

Apremilast [Otezla] - 29

Baricitinib [Olumiant] - 143

Brodalumab [Kyntheum] - 20

Certolizumab [Cimzia] - 60

Dimethyl fumarate [Skilarence] - 0

Etanercept [Benepali] - 415



Etanercept [Enbrel] - 126

Etanercept [Erelzi] - 0

Golimumab [Simponi] - 29

Guselkumab [Tremfya] - 33

Infliximab [Flixabi] - 0

Infliximab [Inflectra] - 125 (Please note that this figure only reflects patient-specific dispensing. It is not a true reflection of patient numbers, as also issued as stock item to the Rheumatology Day Unit.)

Infliximab [Remicade] - <5 (Please note that this figure only reflects patient-specific dispensing. It is not a true reflection of patient numbers, as also issued as stock item to the Rheumatology Day Unit.)

Infliximab [Remsima] - 11

Ixekizumab [Taltz] - 21

Risankizumab [Skyrizi] - 13

Rituximab [MabThera] - <5

Rituximab [Rixathon] - 0

Rituximab [Truxima] - <5 (Please note that this figure only reflects patient-specific dispensing. It is not a true reflection of patient numbers, as also issued as stock item to the Rheumatology Day Unit.)

Sarilumab [Kevzara] - 12

Secukinumab [Cosentyx] - 94

Tildrakizumab [Ilumetri] - 10

Tocilizumab [Ro Actemra] - 91 (Please note that this figure only reflects patient-specific dispensing of the subcutaneous injection. It is not a true reflection of patient numbers as the IV preparation is is issued as stock item to the Rheumatology Day Unit.)

Tofacitinib [Xeljanz] - 54

Upadacitinib [Rinvoq] 0

Ustekinumab [Stelara] - 115

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely

Pam Wenger

Director of Corporate Governance

P. a. wenger